EULAR/ACR classification criteria for paediatric chronic nonbacterial osteomyelitis (CNO)
- PMID: 39966038
- DOI: 10.1016/j.ard.2024.11.006
EULAR/ACR classification criteria for paediatric chronic nonbacterial osteomyelitis (CNO)
Abstract
Objectives: To develop and validate classification criteria for paediatric chronic nonbacterial osteomyelitis (CNO) jointly supported by the European Alliance of Associations for Rheumatology (EULAR) and the American College of Rheumatology (ACR).
Methods: This international initiative had 4 phases: (1) candidate items were proposed in a survey of paediatric rheumatologists, (2) criteria definition and reduction by Delphi and nominal group technique exercises, (3) criteria weighting using multicriteria decision analysis, and (4) refinement of weights and threshold score in a development cohort of 441 patients and validation in another cohort of 514 patients.
Results: The new EULAR/ACR classification criteria for CNO require typical radiographic or magnetic resonance imaging findings and bone pain as an obligatory entry criterion and exclusion criteria of malignancy, infection, vitamin C deficiency, and hypophosphatasia, followed by additive weighted criteria in 5 clinical (site of bone lesions, pattern of bone lesions, age at onset, coexisting conditions, fever) and 4 pathology/laboratory domains (bone biopsy findings if done, anaemia, C-reactive protein level, and erythrocyte sedimentation rate). A total score ≥55 is required for classification as CNO. The new criteria had a sensitivity of 82% and specificity of 98% in the validation cohort.
Conclusions: These new classification criteria for paediatric CNO developed with international input reflect current views about CNO, have high specificity and good sensitivity, and provide a key foundation for future CNO research.
Copyright © 2025 The Authors. Published by Elsevier B.V. All rights reserved.
Conflict of interest statement
Competing interests YZ: ACR, EULAR, CARRA (Grants to Institution, Finance Committee), Bristol-Myer Squibbs (Grants to Institution), Rheumatology Research Foundation (Grants to Institution), CTIP (Grants to Institution), UpToDate CRMO/CNO (Royalties/Licence), Novartis (Consulting Fees to Self), U.S. Provisional Application No. 63/356977 (Patent Issued), Seattle Children's CRMO Warriors Guild (Leadership/Fiduciary Role), American Board of Pediatrics, Pediatric Rheumatology Subboard (Leadership/Fiduciary Role). Melissa SO: CARRA (AF-Small Grants from 2022 to 2024, Total: $48,399.00). AS: EULAR (Fellow with Funding of €15,000.00, Grants or Contracts). JDA: Novartis (Participation on Advisory Board 2023). MLB: Sjogren Foundation (Grants to Institution), Childhood Arthritis and Rheumatology Research Alliance (Grants to Institution). SKL: Time Hearst Foundation Physician Scientist Award (Grants), ACR (Support for Attending Meetings), Hackensack Meridian Health (Support for Attending Meetings), CARRA PFAPA/Autoinflammatory (Work Group Leader), APMC (Pediatrics Committee). TCL: Crohns & Colitis Congress Talk 2024 (Honoraria for Self, Support for Travel), Packard Children's Health Alliance Board of Directors (Board Member, Unpaid), Lupus Foundation of Northern California (Board Member, Unpaid). AL: National Institution of Health Award Number K23AR082966 (Grants to Institution). TSS: Invicro (Consulting Fees to Institution), Hippo Education (Payment to Self). GS: Sobi (Consulting Fees), Novartis (Consulting Fees), AbbVie (Consulting Fees, Payment/Honoraria). LBT: Cassie & Friends Society (Board Member, Unpaid). LFV: Trinds 2022-2025 (Contract for Trials, Payment to Self), Wolters Kluwer 2021 (Payment for Authorship to Self), Scholar Rock 2024 (Support for Travel). SC-YW: Arthritis Foundation Great West Region (Medical Advisory Board, Unpaid), Aicardi Goutieres Syndrome Advocacy Association (ECHO Faculty, Unpaid). KB: Czech Ministry of Health (DRO FNOl, 00098892, Support for the Manuscript). AMH: Seattle Children's Research Institute (Support for the Manuscript, Consulting Fees). FD: UpToDate (Royalties or Licences), ISSAID (Support for Attending Meetings in 2023, Education Committee Chair). CMH: Merck (Unrestricted Research Grant), Novartis (Unrestricted Research Grant Ended in 2022, Advisory Board on the Use of IL-1 blockers in CNO). RML: UpToDate (Royalties or Licences), Elsevier (Royalties or Licences), Sanofi (Consulting Fees to Institution, Participation on Board), Eli Lilly Canada (Consulting Fees to Self, Participation on Board), Sobi (Consulting Fees to Self), Novartis (Consulting Fees to Self, Participation on Board), Akros Pharma (Consulting Fees to Self), Children's Hospital of Philadelphia (Participation on Board). PJF: American Board of Pediatrics (Chair, Payment or Honoraria to Self), Pediatric Rheumatology Subcommittee (Chair, Payment or Honoraria to Self), Current Opinion in Rheumatology Section Editor (Payment or Honoraria to Self), CARRA (Support for Travel), CNO Meeting in Liverpool 2022 (Support for Travel), PRES Invited Speaker 2022 (Support for Travel). RN: ACR/EULAR Development for Classification for Anti-Phospholipid Syndrome and IgG4-Related Diseases (Consulting Fees), Genentech Development of Pediatric Glucocorticoid Toxicity Index (Consulting Fees, Support for Travel). SO: Novartis (Consulting Fees), Sobi (Consulting Fees). Eveline Yawei Wu, ZW, AM, CLA, UKA, BA, SA, EEB-D, OB, YB, DAC, MC, ND, BHE, EF, AI, RSI, AFJ, IK, MK, LKK, KTK, KM, EM, DMM, IM, AM, KDN, FN, KO, MP, TSP, LP, AVR, AR, NDR, AWG, MR, NR, JBS, SMS, TS, ATK, ACT, SY, KCC, and HJG have no conflicts of interest to disclose.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Research Materials
